Literature DB >> 6794971

Kinetics of an orally absorbed aldose reductase inhibitor, sorbinil.

G Foulds, M M O'Brien, J R Bianchine, K H Gabbay.   

Abstract

Kinetics of sorbinil, an orally absorbed reductase inhibitor, were examined in man. Peak plasma concentrations were 0.95 micrograms/ml after a single 50-mg oral dose and 3.6 micrograms/ml after a 250-mg dose. The apparent volume of distribution was 840 ml/kg. Elimination from plasma was slow with a terminal half-life between 6 and 24 hr after dose of 34 to 52 hr and a renal clearance of 6.0 ml/min/1.73 m2. Administration of 50 mg/day for 5 days induced a mean peak serum concentration of 1.9 micrograms/ml. A dose of 250 mg/day for 10 days induced a peak serum concentration of 10.6 micrograms/ml. A mean of one-third of the dose was ultimately recovered unchanged in urine. Sorbinil kinetics make it suitable for once-a-day dosing.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794971     DOI: 10.1038/clpt.1981.222

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Aldose reductase inhibitors and late complications of diabetes.

Authors:  P Benfield
Journal:  Drugs       Date:  1986       Impact factor: 9.546

2.  Sorbinil pharmacokinetics in male and female elderly volunteers.

Authors:  A K Scott; J Webster; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

3.  myo-Inositol and sorbitol in erythrocytes from diabetic patients before and after sorbinil treatment.

Authors:  C Popp-Snijders; M Z Lomecky-Janousek; J A Schouten; E A van der Veen
Journal:  Diabetologia       Date:  1984-11       Impact factor: 10.122

4.  Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.

Authors:  I G Lewin; I A O'Brien; M H Morgan; R J Corrall
Journal:  Diabetologia       Date:  1984-06       Impact factor: 10.122

5.  The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy.

Authors:  J M Lehtinen; S K Hyvönen; M Uusitupa; E Puhakainen; T Halonen; H Kilpeläinen
Journal:  J Neurol       Date:  1986-06       Impact factor: 4.849

6.  Cerebral cortical capillary basement membrane thickening in galactosaemic rats.

Authors:  R N Frank; S Dutta; S E Frank
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

7.  Activated and unactivated forms of human erythrocyte aldose reductase.

Authors:  S K Srivastava; G A Hair; B Das
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

8.  Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.

Authors:  J Fagius; A Brattberg; S Jameson; C Berne
Journal:  Diabetologia       Date:  1985-06       Impact factor: 10.122

9.  Inhibition of Aldose Reductase by Novel Phytocompounds: A Heuristic Approach to Treating Diabetic Retinopathy.

Authors:  Angeline Julius; Remya Rajan Renuka; Waheeta Hopper; P Babu Raghu; Sharmila Rajendran; Senthilkumari Srinivasan; Kuppamuthu Dharmalingam; Amer M Alanazi; Selvaraj Arokiyaraj; S Prasath
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-21       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.